Exploring the efficacy of nivolumab and ipilimumab in renal cell carcinoma: insights from a district hospital cohort study
Our analysis suggests that the combination of nivolumab and ipilimumab for mRCC has an acceptable toxicity profile and can be effectively managed in a district hospital's outpatient clinic. This approach requires close patient monitoring and collaboration with other hospital departments to ensure patient safety and treatment efficacy.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Artur Drobniak
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Łukasz Stokłosa
Institutions
- Jagiellonian University (PL)
- University College of Tourism and Ecology (PL)
- Central Clinical Hospital (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- Reports of Practical Oncology & Radiotherapy
- Published
- 2025-03-21
- DOI
- https://doi.org/10.5603/rpor.104389
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52